Human Intramuscular Hyperimmune Gamma Globulin (hIHGG) Anti-SARS-CoV-2—Characteristics of Intermediates and Final Product

Abstract

This study aims to characterize the intermediates, and the final product (FP) obtained during the production of human intramuscular hyperimmune gamma globulin anti-SARS-CoV-2 (hIHGG anti-SARS-CoV-2) and to determine its stability. Material and methods: hIHGG anti-SARS-CoV-2 was fractionated from 270 convalescent plasma donations with the Cohn method. Prior to fractionation, the plasma was inactivated (Theraflex MB Plasma). Samples were defined using enzyme immunoassays (EIA) for anti-S1, anti-RBD S1, and anti-N antibodies, and neutralization assays with SARS-CoV-2 (VN) and pseudoviruses (PVN, decorated with SARS-CoV-2 S protein). Results were expressed as a titer (EIA) or 50% of the neutralization titer (IC50) estimated in a four-parameter nonlinear regression model. Results: Concentration of anti-S1 antibodies in plasma was similar before and after inactivation. Following fractionation, the anti-S1, anti-RBD, and anti-N (total tests) titers in FP were concentrated approximately 15-fold from 1:4 to 1:63 (1800 BAU/mL), 7-fold from 1:111 to 1:802 and from 1:13 to 1:88, respectively. During production, the IgA (anti-S1) antibody titer was reduced to an undetectable level and the IgM (anti-RBD) titer from 1:115 to 1:24. The neutralizing antibodies (nAb) titer increased in both VN (from 1:40 to 1:160) and PVN (IC50 from 63 to 313). The concentration of specific IgG in the FP did not change significantly for 14 months. Conclusions: The hIHGG anti-SARS-CoV-2 was stable, with concentration up to approximately 15-fold nAb compared to the source plasma pool.

Enhancing the therapeutic activity of hyperimmune IgG against chikungunya virus using FcγRIIIa affinity chromatography

“…Hyperimmune immunoglobulin therapy involves the administration of purified and concentrated immunoglobulins from convalescent donors that have high antibody titers against the pathogen of interest, with the main component being IgG (6,7). Such therapies are approved against several viruses including cytomegalovirus, hepatitis A, hepatitis B, rabies, and varicella zoster viruses, but their development against emerging viruses such as influenza, Ebola, Zika, and SARS-CoV-2 has been challenged by lack of efficacy or the potential for antibodydependent enhancement (ADE) of infection (8)(9)(10)(11)(12).…”

Viruses Special Issue “Transfusion-Transmitted Viral Infections”

“…In addition, blood transfusion services play an important, but often underappreciated, role in general public health, as illustrated by the experience of the Canadian Blood Services reported by Drews, O’Brien, and their colleagues [ 11 , 12 ]. Blood services’ involvement in public health includes support for the surveillance of emerging viral infections beyond blood-borne viruses (i.e., SARS-CoV2) using the blood donor population as a sentinel group (O’Brien et al [ 12 ]), together with the detection and rapid treatment of unsuspected viral infections (van den Berg et al [ 13 ]) and the characterization and development of new therapeutics (Lachert et al [ 14 ]).…”